May 24 (Reuters) - A panel of independent experts to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar. (Reporting by Sriparna Roy and Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)